Profile: Lupin CFO Swaminathan, The ‘Constant Learner'
CFOs are known for talking about their top and bottom lines, but not so much about what makes them tick. Here we give you a peek into the life story of Lupin CFO Ramesh Swaminathan, who shares with Scrip why he made the shift from Henkel in Germany to the Indian firm, M&A learnings, admiration for peer Sun Pharma and his own career ambitions.
You may also be interested in...
Mylan has struck a deal to commercialize Lupin's biosimilar Enbrel (etanercept), continuing to seize opportunities beyond existing alliances to ensure an early play in certain key markets. Longstanding Mylan partner Biocon maintains that it won't lose out either, though the outlook for their partnered etanercept is unclear, at least for now.
Lupin ended the fourth quarter in the red hit by an impairment provision related to the "underperforming" assets of its Gavis acquisition but the firm's US inhalation pipeline appears to have made some progress, including a filing for tiotropium dry powder inhaler (DPI). Early stage biosimilars under development include, among others, versions of Neulasta and Xgeva/Prolia.
Lupin has snapped up Symbiomix Therapeutics in the US as it evolves its business from a predominantly straight-generics play to a model with an increasing mix of complex generics, specialty medicines and biosimilars. The latest deal gives Lupin access to a therapy in the women’s health segment recently approved by the US FDA.